Adult T-Cell Leukemia/Lymphoma · line 1 · CHOEP (cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone), 6 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CHOEP |
| ID | IND-ATLL-1L-AGGRESSIVE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ATLL |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB. Mogamulizumab — НСЗУ availability в Україні обмежена. Без mogamulizumab — lower response, але CHOEP + allo-SCT все одно best available.
Used By
Algorithms
ALGO-ATLL-1L- ALGO-ATLL-1L
Indication
IND-ATLL-1L-INDOLENT-AZT-IFN- IND-ATLL-1L-INDOLENT-AZT-IFN